Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Jianhong Chu"'
Autor:
Dongpeng Jiang, Haiwen Huang, Huimin Qin, Koukou Tang, Xiangru Shi, Tingting Zhu, Yuqing Gao, Ying Zhang, Xiaopeng Tian, Jianhong Fu, Weiwei Qu, Weilan Cai, Yang Xu, Depei Wu, Jianhong Chu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience
Externí odkaz:
https://doaj.org/article/eb2d7862124a4bf180e034d1c05e70ed
Autor:
Zhongzheng Li, Xin Liu, Lan Wang, Huabin Zhao, Shenghui Wang, Guoying Yu, Depei Wu, Jianhong Chu, Jingjing Han
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionAcute myeloid leukemia (AML) is a type of blood cancer that is identified by the unrestricted growth of immature myeloid cells within the bone marrow. Despite therapeutic advances, AML prognosis remains highly variable, and there is a lac
Externí odkaz:
https://doaj.org/article/77a636f2a0614c4ea2c686a737380f33
Autor:
Fang Xu, Dongpeng Jiang, Jialu Xu, Huaxing Dai, Qin Fan, Ziying Fei, Beilei Wang, Yue Zhang, Qingle Ma, Qianyu Yang, Yitong Chen, Edikan A. Ogunnaike, Jianhong Chu, Chao Wang
Publikováno v:
Cell Reports, Vol 42, Iss 10, Pp 113138- (2023)
Summary: Advances in the development of therapeutic extracellular vesicles (EVs) for cancer immunotherapy have allowed them to emerge as an alternative to cell therapy. In this proof-of-concept work, we develop bispecific EVs (BsEVs) by genetically e
Externí odkaz:
https://doaj.org/article/fd2d0ad132a647379ec4f1b77e81fa5a
Autor:
Lihong Zhang, Haifei Yang, Chongsheng Qian, Jihao Zhou, Qian Zhu, Yibin Jiang, Shuo Liu, Xiaochen Chen, Ting Xu, Changju Qu, Caixia Li, Zhengming Jin, Jianhong Chu, Xinyou Zhang, Depei Wu, Haiwen Huang
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 404-411 (2022)
Objectives The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma.Patients and methods We retrospectively reviewed the records of patients with lymphoma who underwent auto-SCT with
Externí odkaz:
https://doaj.org/article/12a9e5b2c6b54c508988f4a6d827f7ac
Autor:
Weili Wang, Huizhen Zheng, Jun Jiang, Zhi Li, Dongpeng Jiang, Xiangru Shi, Hui Wang, Jie Jiang, Qianqian Xie, Meng Gao, Jianhong Chu, Xiaoming Cai, Tian Xia, Ruibin Li
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Tumour hypoxia is an important factor in tumorigenesis and cancer therapy. Here, the authors present a micro oxygenation factory, capable of providing an oxygen supply through photosynthesis, and demonstrate its utility in cancer therapy.
Externí odkaz:
https://doaj.org/article/84ec028958754b919161081a38882a51
Autor:
Jialu Xu, Qingle Ma, Yue Zhang, Ziying Fei, Yifei Sun, Qin Fan, Bo Liu, Jinyu Bai, Yue Yu, Jianhong Chu, Jingrun Chen, Chao Wang
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Components of the yeast cell wall, including but not limited to β-glucan, have been reported to act as danger signals and promote immune responses. Here the authors report the design and anti-tumor immune responses elicited by yeast cell wall-based
Externí odkaz:
https://doaj.org/article/a2370945577b4802b242c99158b442ee
Autor:
Fangjie Wang, Meng Meng, Banghui Mo, Yao Yang, Yan Ji, Pei Huang, Wenjing Lai, Xiaodong Pan, Tingting You, Hongqin Luo, Xiao Guan, Yafei Deng, Shunzong Yuan, Jianhong Chu, Michael Namaka, Tiffany Hughes, Lilin Ye, Jianhua Yu, Xiaohui Li, Youcai Deng
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
The metabolic regulator protein family, mTOR, regulate natural killer (NK) cell development and function, but the underlying mechanism is unclear. Here, the authors show that Raptor/mTORC1 and Rictor/mTORC2 form a feedback crosstalk network to varieg
Externí odkaz:
https://doaj.org/article/aed5a9a2b75b4c99ac71c6c1c1c72f87
Publikováno v:
China Communications. :1-18
Autor:
Jianhua Yu, Craig C. Hofmeister, Xue-Feng Bai, Xiaoming He, Steven M. Devine, Qi-En Wang, Chang-Hyuk Kwon, Ling Yi, Tiffany Hughes, Yong Peng, Jianying Zhang, Youcai Deng, Shun He, Jianhong Chu
PDF file - 1721KB, Detailed methods for cell culture, retroviral transfection, generation of RPMI-8226 cells expressing CS1. Figure S1, killing of 293T cells expressing CS1. Figure S2, activation of T cell subsets. Figure S3, IM-9 in vivo experiment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a17ec8a17202f47929f404574758291d
https://doi.org/10.1158/1078-0432.22451724
https://doi.org/10.1158/1078-0432.22451724
Autor:
Jianhua Yu, Craig C. Hofmeister, Xue-Feng Bai, Xiaoming He, Steven M. Devine, Qi-En Wang, Chang-Hyuk Kwon, Ling Yi, Tiffany Hughes, Yong Peng, Jianying Zhang, Youcai Deng, Shun He, Jianhong Chu
Purpose: Our goal is to test whether CS1 could be targeted by chimeric antigen receptor (CAR) T cells to treat multiple myeloma (MM).Experimental Design: We generated a retroviral construct of a CS1-specific CAR and engineered primary human T cells e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5f95c239099586c82ef9d24fa24868
https://doi.org/10.1158/1078-0432.c.6522267.v1
https://doi.org/10.1158/1078-0432.c.6522267.v1